| Drug ID: | Drug158 |
|---|
| Drug Name: | SPH3127 |
|---|
| CID: | 117877477 |
|---|
| DrugBank ID: | DB19108 |
|---|
| Modality: | Small Molecule |
|---|
| Groups: | NULL |
|---|
| US Approved: | NULL |
|---|
| Other Approved: | NULL |
|---|
| Identifier: |
NCT05019742, ,
NCT05770609
|
|---|
| Molecular Formula: | C22H32N6O4 |
|---|
| Molecular Weight: | 444.5 g/mol |
|---|
| Isomeric SMILES: | CC1=NC2=C(C=C1)C(=NN2CCCNC(=O)OC)[C@@H](C)N(C3CC3)C(=O)[C@H]4CNCCO4 |
|---|
| Synonyms: | SPH3127; sitokiren; 1399849-02-5; SPH-3127; C2M78A9V6Z; compound 18 [PMID: 35939295]; compound 18 (PMID: 35939295); Carbamic acid, N-(3-(3-((1R)-1-(cyclopropyl((2R)-2-morpholinylcarbonyl)amino)ethyl)-6-methyl-1H-pyrazolo(3,4-b)pyridin-1-yl)propyl)-, methyl ester; UNII-C2M78A9V6Z; sitokiren [INN] |
|---|
| Phase 0: | 0 |
|---|
| Phase 1: | 0 |
|---|
| Phase 2: | 0 |
|---|
| Phase 3: | 0 |
|---|
| Phase 4: | 0 |
|---|
| Description: | NULL |
|---|
-
-
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
| dt1207 |
117877477 |
Sph3127 |
5972 |
REN
|
Homo sapiens (human) |
|
Inhibitor |
| dt1208 |
117877477 |
Sph3127 |
5972 |
REN
|
Homo sapiens (human) |
31494843 |
Renin inhibitor |
| dt1209 |
117877477 |
Sph3127 |
5972 |
REN
|
Homo sapiens (human) |
35939295 |
Inhibition |
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
| NCT05019742 |
Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis |
PHASE2 |
RECRUITING |
Shanghai Pharma Biotherapeutics USA Inc. |
Ulcerative Colitis |
DRUG: SPH3127|DRUG: Placebo |
Details |
| NCT05770609 |
A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis |
PHASE2 |
RECRUITING |
Shanghai Pharmaceuticals Holding Co., Ltd |
Mild to Moderate Ulcerative Colitis |
DRUG: SPH3127 Tablets with Dose A|DRUG: SPH3127 T… |
Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
| No data available |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
| No data available |
PMID: 40393940
Year: 2025
Relationship Type:
Treatment
Score: 9.5
BACKGROUND: Emerging evidence suggests that the renin-angiotensin system plays an important role in the pathogenesis of inflammatory bowel disease, b…
